RecruitingNCT02573636

The Predictive Value of Coexisting TMPRSS2-ERG Gene Fusion and PTEN Deletion in Prostate Cancer Patients with Biochemical Failure Status Post Salvage or Radical Radiation Therapy

Sponsor

Sir Mortimer B. Davis - Jewish General Hospital

Enrollment

208 participants

Start Date

Mar 1, 2016

Study Type

OBSERVATIONAL

Conditions

Prostate Cancer

Summary

The objective of the study is to evaluate the predictive value of TMPRSS2-ERG gene fusion and PTEN in patients with high risk prostate cancer treated with first line LHRH agonist after biochemical failure.

Eligibility

Sex: MALEMin Age: 18 Years

Inclusion Criteria5

T3a +
PSA \> 20
Gleason 8 or higher
Karnofsky performance status ≥ 70.
Signed study-specific informed consent

Exclusion Criteria1

Locations(9)

CIUSSS du Saguenay-Lac-St-Jean/CSSS de Chicoutimi

Chicoutimi, Quebec, Canada

CISSS de la Montérégie-Centre - Hôpital Charles-LeMoyne

Greenfield Park, Quebec, Canada

CISSS de Laval - Hôpital de la Cité-de-la-santé de Laval

Laval, Quebec, Canada

CIUSSS de l'Est-de-l'Île-de-Montréal - Hôpital Maisonneuve-Rosemont

Montreal, Quebec, Canada

Jewish General Hospital, McGill University

Montreal, Quebec, Canada

MUHC - Cedars Cancer Center

Montreal, Quebec, Canada

CHU - L'Hôtel-Dieu de Québec

Québec, Quebec, Canada

CIUSSS de l'Estrie - Hôpital Fleurimont

Sherbrooke, Quebec, Canada

CIUSSS de la Mauricie-et-du-centre-du Quebec - Centre hospitalier régional de Trois-Rivières

Trois-Rivières, Quebec, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02573636

Related Trials

Predictors of Mental Health in Men With Prostate Cancer Undergoing a Patient Empowerment Program

NCT0489583916 locations

64Cu-SAR-bisPSMA Positron Emission Tomography: A Phase 3 Study of Participants With Biochemical Recurrence of Prostate Cancer

NCT0697084728 locations

Mechanisms of Resistance to PSMA Radioligand Therapy

NCT054354953 locations

INSIGHT-PCa: MRI- and PHI-Guided Risk-Adapted Strategy for Prostate Cancer Diagnosis

NCT073986901 location

Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy

NCT0678067052 locations